2023
6 March, 2023
Notice of Annual General Meeting in FluoGuide A/S
The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39 29 64 38 (the...
27 February, 2023
FluoGuide updates on recruitment in phase IIb aggressive brain cancer trial with FG001
FluoGuide A/S (“FluoGuide” or the “Company”) provides an update on the clinical timelines for the ongoing clinical...
2 February, 2023
FluoGuide appoints Ole Larsen as CFO
FluoGuide A/S (“FluoGuide” or the “Company”) has appointed Ole Larsen as Chief Financial Officer (“CFO”)...
25 January, 2023
CFO acquired shares in FluoGuide
FluoGuide A/S (“FluoGuide” or the “Company”) announce that the CFO of FluoGuide, Henrik Hang, has acquired...
Copenhagen, Denmark, 9 January 2023 - FluoGuide A/S ("FluoGuide" or the "Company") is pleased to announce the positive...
2022
In Q3 2022, FluoGuide made important progress and received approvals from Danish authorities to initiate the clinical phase IIb trial...
21 November, 2022
FluoGuide has enrolled the first patient in the phase IIa trial in head and neck cancer
The phase IIa trial is designed to obtain proof-of-concept in head and neck cancer for our uPAR platform technology used to guide surgical...
8 November, 2022
FluoGuide reaches milestone with FG001 for phase III clinical supply
FluoGuide has successfully collaborated with its supplier PolyPeptide since the very first synthesis of the FG001 API (Active Pharmaceutical...